BioCryst Pharmaceuticals | BCRX - Ebit

Stock Price
9.57
Daily Change
-0.11 -1.09%
Monthly
2.85%
Yearly
32.48%
Q2 Forecast
9.30

BioCryst Pharmaceuticals reported $260.38M in EBIT for its fiscal quarter ending in December of 2025.





Ebit Change Date
Alnylam Pharmaceuticals USD 29.4M 59.36M Dec/2025
BioCryst Pharmaceuticals USD 260.38M 230.79M Dec/2025
Chugai Pharma JPY 169.01B 12.52B Dec/2025
Daiichi Sankyo JPY 89.54B 42.01B Dec/2025
DBV Technologies USD -34.28M 6.83M Sep/2025
Enanta Pharmaceuticals USD -23.54M 6.31M Dec/2024
Gilead Sciences USD 2.96B 551M Dec/2025
GlaxoSmithKline GBP 1.44B 1.35B Dec/2025
Glaxosmithkline GBP 2.3B 1.46B Dec/2025
Incyte USD 383.88M 47.44M Dec/2025
Ionis Pharmaceuticals USD -215M 54.82M Dec/2025
Karyopharm Therapeutics USD -17.84M 8.44M Dec/2025
Neurocrine Biosciences USD 227.9M 11.4M Dec/2025
Novavax USD 20.94M 100.32M Dec/2025
PTC Therapeutics USD -81.62M 85.11M Dec/2025
Regeneron Pharmaceuticals USD 898.6M 211.3M Dec/2025
Roche Holding CHF 9.56B 2.1B Dec/2025
Sarepta Therapeutics USD -410.08M 347.2M Dec/2025
Ultragenyx Pharmaceutical USD -114M 56.89M Dec/2025
Vertex Pharmaceuticals USD 1.26B 24.5M Dec/2025